Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting

Journal of Asthma and Allergy

Volumn , Issue 5, 2012, Pages 1-9

  Ali, Ayad K ^a   Hartzema, Abraham G ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Adverse event reporting system; Arterial thrombotic events; Omalizumab; Postmarketing safety surveillance

Indexed keywords

AMINOPHYLLINE; BECLOMETASONE; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CROMOGLYCATE DISODIUM; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL; MOMETASONE FUROATE; MONTELUKAST; NEDOCROMIL; OMALIZUMAB; OXITROPIUM BROMIDE; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE; ZAFIRLUKAST; ZILEUTON;

ALLERGIC ASTHMA; ARTERY THROMBOSIS; ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SAFETY; HUMAN; POSTMARKETING SURVEILLANCE; RISK ASSESSMENT;

EID: 84862545173     PISSN: 11786965     EISSN: None     Source Type: Journal    
DOI: 10.2147/JAA.S29811     Document Type: Article

References (16)

1. Buhl R. Anti-IgE antibodies for the treatment of asthma. Curr Opin Pulm Med. 2005;11(1):27-34.
2. Food and Drug Administration. FDA approved drug products (Drugs @ FDA), updated August 2011. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed August 3, 2011.
3. American Society for Health-System Pharmacists. AHFS Drug Information Essentials: 2004-2005. Omalizumab. Bethesda, MD: American Society for Health-System Pharmacists; 2004.
4. Medicines and Healthcare Regulatory Agency. Omalizumab: Potential risk of arterial thrombotic events. Available from: http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con108718.pdf. Accessed August 3, 2011.
5. World Health Organization. Omalizumab: Potential risk of arterial thrombotic events. 2011. Available from: http://www.who.int/medicines/publications/Newsletter_2-2011.pdf. Accessed August 3, 2011.
6. Long AA, Fish JE, Rahmaoui A, et al. Baseline characteristics of patients enrolled in EXCELS: a cohort study. Ann Allergy Asthma Immunol. 2009; 103(3):212-219.
7. Food and Drug Administration. Postmarket drug safety infor mation for patients and providers. Early communication about an ongoing safety review of omalizumab (marketed as Xolair). July 16, 2009. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/DrugSafetyInformationforHeath careProfessionals/ucm172218.htm. Accessed August 3, 2011.
8. Food and Drug Administration. Adverse Event Reporting System (AERS): Latest quarterly data fles. April 18, 2011. Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInforma tion/Surveillance/AdverseDrugEffects/ucm082193.htm. Accessed May 12, 2011.
9. Ali AK. Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a frst-in-class direct renin inhibitor. Ther Clin Risk Manag. 2011;7:337-344.
10. Clinical Pharmacology [online database]. Tampa, FL: Gold Standard Inc, 2011. Available from: http://www.clinicalpharmacology.com. Updated August 2011. Accessed March 29, 2012.
11. Bate A, Edwards IR. Data mining techniques in pharmacovigilance. In: Hartzema AG, Tilson HH, Chan KA, editors. Pharmacoepidemiology and Therapeutic Risk Management. 1st ed. Cincinnati, OH: Harvey Whitney Books Co; 2008.
12. Food and Drug Administration. CFR-Code of Federal Regulations Title 21. Updated April 1, 2011. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.32. Accessed November 11, 2011.
13. Food and Drug Administration. Staff manual guide: Chapter 53; Postmarketing surveillance and epidemiology: human drugs. Adverse drug effects. Updated May 12, 2010. Available from: http://www.fda. gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/ ucm129115.htm. Accessed November 11, 2011.
14. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. MedWatch Online Voluntary Reporting Form (3500). Updated October 5, 2011. Available from: https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm. Accessed November 13, 2011.
15. Inman WHW. Detection and investigation of drug safety problems. In: Gent M, Shigamatsu I, editors. Epidemiological Issues in Reported Drug-Induced Illnesses. Ontario, Canada: McMaster University Library Press; 1978.
16. Prandoni P. Venous and arterial thrombosis: two aspects of the same disease? Clin Epidemiol. 2009;1:1-6.